SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference.
A Pre-recorded presentation will be available on Monday, January 10th at 7:00 am Eastern Time. Interested parties may access a webcast of the presentation on the investor section of the Company’s website at www.Aziyo.com
About Aziyo Biologics
Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.
Media:
Courtney Guyer
Aziyo Biologics, Inc.
PR@aziyo.com
Investors:
Leigh Salvo
Gilmartin Group
investors@aziyo.com
WELLESLEY, MA / ACCESS Newswire / January 12, 2026 / MDaudit, an award-winning cloud-based continuous…
WELLESLEY, MA / ACCESS Newswire / January 12, 2026 / MDaudit, an award-winning cloud-based continuous…
Fast-Growing Rental Company Honored for Supply Chain Excellence Supporting Hospitals HOUSTON, TEXAS / ACCESS Newswire…
Fast-Growing Rental Company Honored for Supply Chain Excellence Supporting Hospitals HOUSTON, TEXAS / ACCESS Newswire…
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing…
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing…